[Molecular targeted therapy for renal cell carcinoma].
Renal cell carcinoma (RCC) accounts for approximately 2% of all cancer cases worldwide. Metastatic disease is often present at the time of diagnosis of RCC and its poor response to chemotherapy and radiotherapy causes poor prognosis. Immunotherapy is relatively effective for RCC, but the response rate is approximately 15-20%. Therefore, new therapeutic approaches are necessary for these patients with metastatic RCC. Recently, the mechanisms responsible for the growth of RCC have been clarified, and molecular targeted therapy has been developed. In this paper, we review the new molecular targeted therapeutic agents effective for RCC.
Mizutani
Yoichi
Y
Department of Urology, Kyoto Prefectural University of Medicine.
Nakanishi
Hiroyuki
H
Mizuno
Masaaki
M
Yoshida
Jun
J
Miki
Tsuneharu
T
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D051017:Apoptosis Regulatory Proteins; D001557:Benzenesulfonates / Q000008:administration & dosage; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D016503:Drug Delivery Systems; D006801:Humans; D007211:Indoles / Q000008:administration & dosage; D016899:Interferon-beta / Q000008:administration & dosage; D047908:Intracellular Signaling Peptides and Proteins / Q000008:administration & dosage; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008081:Liposomes; D024101:Mitochondrial Proteins / Q000008:administration & dosage; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000008:administration & dosage; D011758:Pyrroles / Q000008:administration & dosage; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077157:Sorafenib; D000077210:Sunitinib
D000970:Antineoplastic Agents; D051017:Apoptosis Regulatory Proteins; D001557:Benzenesulfonates; C412403:DIABLO protein, human; D007211:Indoles; D047908:Intracellular Signaling Peptides and Proteins; D008081:Liposomes; D024101:Mitochondrial Proteins; D010671:Phenylurea Compounds; D011725:Pyridines; D011758:Pyrroles; D009536:Niacinamide; C401859:temsirolimus; D016899:Interferon-beta; D000077157:Sorafenib; D000077210:Sunitinib; D020123:Sirolimus